205 related articles for article (PubMed ID: 33981295)
21. Targeted Genome Editing of Virulent Phages Using CRISPR-Cas9.
Lemay ML; Renaud AC; Rousseau GM; Moineau S
Bio Protoc; 2018 Jan; 8(1):e2674. PubMed ID: 34179229
[TBL] [Abstract][Full Text] [Related]
22. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9.
Hynes AP; Rousseau GM; Lemay ML; Horvath P; Romero DA; Fremaux C; Moineau S
Nat Microbiol; 2017 Oct; 2(10):1374-1380. PubMed ID: 28785032
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of CRISPR-Cas9 with Bacteriophage Proteins.
Rauch BJ; Silvis MR; Hultquist JF; Waters CS; McGregor MJ; Krogan NJ; Bondy-Denomy J
Cell; 2017 Jan; 168(1-2):150-158.e10. PubMed ID: 28041849
[TBL] [Abstract][Full Text] [Related]
24. The CRISPR-Cas system - from bacterial immunity to genome engineering.
Czarnek M; Bereta J
Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):901-16. PubMed ID: 27594566
[TBL] [Abstract][Full Text] [Related]
25. Continuous Multiplexed Phage Genome Editing Using Recombitrons.
Fishman CB; Crawford KD; Bhattarai-Kline S; Zhang K; González-Delgado A; Shipman SL
bioRxiv; 2023 Mar; ():. PubMed ID: 36993281
[TBL] [Abstract][Full Text] [Related]
26. Engineering T4 Bacteriophage for
Dong J; Chen C; Liu Y; Zhu J; Li M; Rao VB; Tao P
ACS Synth Biol; 2021 Oct; 10(10):2639-2648. PubMed ID: 34546037
[TBL] [Abstract][Full Text] [Related]
27. Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions.
Jia HJ; Jia PP; Yin S; Bu LK; Yang G; Pei DS
Front Microbiol; 2023; 14():1172635. PubMed ID: 37323893
[TBL] [Abstract][Full Text] [Related]
28. [CRISPR/Cas systems in genome engineering of bacteriophages].
Liang CJ; Meng FM; Ai YC
Yi Chuan; 2018 May; 40(5):378-389. PubMed ID: 29785946
[TBL] [Abstract][Full Text] [Related]
29. Selection of Genetically Modified Bacteriophages Using the CRISPR-Cas System.
Manor M; Qimron U
Bio Protoc; 2017 Aug; 7(15):. PubMed ID: 28804739
[TBL] [Abstract][Full Text] [Related]
30. Engineering Bacteriophages as Versatile Biologics.
Kilcher S; Loessner MJ
Trends Microbiol; 2019 Apr; 27(4):355-367. PubMed ID: 30322741
[TBL] [Abstract][Full Text] [Related]
31. Targeted Mutagenesis of Guinea Pig Cytomegalovirus Using CRISPR/Cas9-Mediated Gene Editing.
Bierle CJ; Anderholm KM; Wang JB; McVoy MA; Schleiss MR
J Virol; 2016 Aug; 90(15):6989-6998. PubMed ID: 27226370
[TBL] [Abstract][Full Text] [Related]
32. Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens.
Khambhati K; Bhattacharjee G; Gohil N; Dhanoa GK; Sagona AP; Mani I; Bui NL; Chu DT; Karapurkar JK; Jang SH; Chung HY; Maurya R; Alzahrani KJ; Ramakrishna S; Singh V
Bioeng Transl Med; 2023 Mar; 8(2):e10381. PubMed ID: 36925687
[TBL] [Abstract][Full Text] [Related]
33. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
34. Optimization of T4 phage engineering via CRISPR/Cas9.
Duong MM; Carmody CM; Ma Q; Peters JE; Nugen SR
Sci Rep; 2020 Oct; 10(1):18229. PubMed ID: 33106580
[TBL] [Abstract][Full Text] [Related]
35. Endogenous CRISPR-Cas System-Based Genome Editing and Antimicrobials: Review and Prospects.
Li Y; Peng N
Front Microbiol; 2019; 10():2471. PubMed ID: 31708910
[TBL] [Abstract][Full Text] [Related]
36. Development of a RecE/T-Assisted CRISPR-Cas9 Toolbox for Lactobacillus.
Huang H; Song X; Yang S
Biotechnol J; 2019 Jul; 14(7):e1800690. PubMed ID: 30927506
[TBL] [Abstract][Full Text] [Related]
37. Editing of the Bacillus subtilis Genome by the CRISPR-Cas9 System.
Altenbuchner J
Appl Environ Microbiol; 2016 Sep; 82(17):5421-7. PubMed ID: 27342565
[TBL] [Abstract][Full Text] [Related]
38. Phage-Encoded Anti-CRISPR Defenses.
Stanley SY; Maxwell KL
Annu Rev Genet; 2018 Nov; 52():445-464. PubMed ID: 30208287
[TBL] [Abstract][Full Text] [Related]
39. Covalent Modification of Bacteriophage T4 DNA Inhibits CRISPR-Cas9.
Bryson AL; Hwang Y; Sherrill-Mix S; Wu GD; Lewis JD; Black L; Clark TA; Bushman FD
mBio; 2015 Jun; 6(3):e00648. PubMed ID: 26081634
[TBL] [Abstract][Full Text] [Related]
40. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
